Vitro Biopharma, Inc. (VTRO)

Chart not available yet

Data will show when the stock starts trading.

Market Cap	40.29M
Revenue (ttm)	2.04M +102.1%
Net Income	-5.85M
EPS	-0.80
Shares Out	7.33M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	n/a
Previous Close	n/a
Day's Range	n/a
52-Week Range	n/a
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	n/a

About VTRO

Vitro Biopharma is an innovative biotechnology company targeting autoimmune diseases and inflammatory disorders. Through our proprietary platform, AlloRx Stem Cell therapy, we are developing novel cellular therapeutic candidates that are derived from culture-expanded mesenchymal stem cells (“MSCs”) sourced from the Wharton’s jelly of umbilical cords (“UCs”) donated by healthy volunteers following childbirth. In the United States, we are authorized to conduct two clinical trials under two U.S. Food and Drug Administration Investigational New Dru...

• Industry: Health Care
• Sector: Biotechnology
• Founded: 1986
• Employees: 12
• Stock Exchange: NYSEAMERICAN
• Ticker Symbol: VTRO
• Website: https://www.vitrobiopharma.com/

Financial Performance

Data Source: SEC filings Last updated: Aug 19, 2026

The data for this page was gathered manually by the Stock Analysis team, from official company filings available on SEC.gov.

Data Sources Report a data error